Mobile

A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1β Converting Enzyme Inhibitor, in Patients with Muckle-Wells Syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000283-27

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Investigate safety/tolerability, anti-inflammatory effect and pharmacokinetics of VX-765 in patients with Muckle-Wells Syndrome.

Critère d'inclusion

  • Muckle-Wells Syndrome

Liens